New Delhi: Dr. Reddy’s Laboratories announced on Thursday that it has signed a licensing
agreement with Takeda Pharmaceutical Company to commercialize Vonoprazan tablets in
India. Vonoprazan is an innovative, orally active potassium-competitive acid blocker (PCAB)
used for treating reflux esophagitis and other acid-related disorders.
The Hyderabad-based pharmaceutical company stated that it has entered into a non-exclusive
patent licensing deal with Takeda for the commercialization of the product. Dr. Reddy’s will
market the Vonoprazan tablets under its own brand name, Vono, in 10mg and 20mg strengths.
“This non-exclusive patent licensing agreement with Takeda is part of our ongoing efforts to
provide innovative medicines to patients in India through strategic collaborations, addressing
unmet needs and improving standards of care,” said MV Ramana, CEO of Branded Markets
(India & Emerging Markets) at Dr. Reddy’s.
Shares of Dr. Reddy’s closed 0.33 percent higher at Rs 6,665.10 each on the BSE.
